Evidence map›Paper›PMID 42412034›Full record

ReviewJournal of Parkinson's disease2026

Bridging the global Parkinson's divide: Technology as a structural solution for equitable and brain health-integrated care.

Roongroj Bhidayasiri, Ruth B Schneider, Walter Maetzler, Alberto J Espay, Thien Thien Lim, Appasone Phoumindr, Hrishikesh Kumar, Andrea Pilotto, Bastiaan R Bloem

Abstract readReview
In one paragraph

Review in Journal of Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. What's in a name? reframing advanced Parkinson's disease as a multidimensional state.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Roongroj BhidayasiriChulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.ORCID 0000-0002-6901-2064
Ruth B SchneiderDepartment of Neurology, University of Rochester, Rochester, New York, USA.ORCID 0000-0001-8094-4041
Walter MaetzlerDepartment of Neurology, University Hospital Schleswig-Holstein and Kiel University, Kiel, Germany.
Alberto J EspayJames J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, USA.ORCID 0000-0002-3389-136X
Thien Thien LimNeurology Unit, Island Hospital, Georgetown, Penang, Malaysia.
Appasone PhoumindrDepartment of Internal Medicine, Faculty of Medicine, University of Health Sciences, Vientiane Capital, Lao PDR.
Hrishikesh KumarDepartment of Neurology, Institute of Neurosciences Kolkata (I-NK), Kolkata, West Bengal, India.
Andrea PilottoDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Bastiaan R BloemDepartment of Neurology, Radboud University Medical Center Nijmegen; Donders Institute for Brain, Cognition, and Behavior, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is the fastest-growing neurodegenerative disorder worldwide, with projections exceeding 25 million people by 2050. Its burden, however, is unevenly distributed. Many low- and middle-income countries face rapidly rising prevalence alongside profound shortages in neurological workforce, infrastructure, and access to specialised care and essential therapies. This global "Parkinson's divide" reflects not merely a funding gap, but a structural mismatch between disease burden and health-system capacity. Traditional clinic-centred models cannot scale to meet this expanding demand.This article argues that technology, when responsibly implemented, offers a structural response to this capacity gap. Telemedicine expands access by decoupling specialist expertise from geography. Wearable and domestic sensor-based technologies extend clinical visibility beyond episodic encounters, capturing real-world fluctuations, mobility changes, falls, and sleep disturbances. Artificial intelligence, positioned as augmented rather than autonomous intelligence, can transform high-volume longitudinal data into actionable insights that support triage, task-sharing, and continuity across distributed care networks. Mobile health platforms further strengthen patient agency through structured self-management and co-designed digital ecosystems.Yet innovation alone is not sufficient. Impact depends on feasibility, interoperability, workforce development, governance, and equity-first design, particularly in resource-constrained settings. Embedded within hybrid care models and life-course brain health frameworks, digital technologies can shift PD management from episodic symptom control toward longitudinal stewardship of function and resilience, helping to convert scarcity into distributed capability and narrow global inequities in Parkinson's care for our future generations.

Indexed as

artificial intelligencebrain healthdigital healthhealth equityParkinson's diseasetelemedicine

Identifiers

PMID42412034
PMCPMC13443343

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.